Vaxart Inc. Stock
Price
Target price
?
?
2.040%
0.01
2.040%
-
07:46 / Stuttgart Stock Exchange
WKN: A2JD8X / Symbol: AVIR / Name: Vaxart / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Vaxart Inc. Stock
Vaxart Inc. gained 2.040% today.
For the coming years our community has positive and negative things to say abot the Vaxart Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | 2.040% | 4.000% | 86.113% | -27.018% | 85.714% | -46.314% | -90.796% |
| aTyr Pharma Inc | - | 0.000% | 16.466% | -83.140% | -3.333% | -72.008% | -81.988% |
| Larimar Therapeutics Inc. | 0.710% | -8.219% | -6.294% | -17.791% | -19.277% | -30.570% | -82.710% |
| Inotiv Inc. | 0.960% | -9.170% | -19.223% | -90.459% | -2.804% | -92.949% | -96.562% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)
Penny stocks attract speculative investors looking for high-risk/high-reward opportunities. That means looking for companies with disruptive technologies, that are part of an emerging trend, or
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
